Human Immunodeficiency Virus | Access and Reimbursement | US | 2016
The HIV therapy market is growing as a result of the uptake of new premium-priced antiretroviral (ARV) agents, particularly the latest single-tablet regimens (STRs), which offer improved safety and tolerability. Human Immunodeficiency Virus | Access & Reimbursement | U.S. content examines the market access factors that influence the success of HIV ARV therapies in the U.S. market. The series is based on primary research with U.S. infectious disease specialists and internal medicine/primary care physicians, as well as with MCO medical directors and pharmacy directors. It explores how payers and physicians interact and how reimbursement decisions influence the prescribing and uptake of specific HIV therapies at the brand level.
